PROComb:随机化优化剂量组合的实用稳健设计
PROComb 是一种用于药物联合试验的两阶段随机化设计,第一阶段整合多源数据探索剂量组合空间并建立治疗剂量空间(TDS),第二阶段将患者随机分配至推荐剂量组合以识别最佳生物剂量组合(OBDC);模拟研究显示其操作特性优于传统基于模型和模型辅助设计。
要点
- 第一阶段整合毒性、疗效和PD数据自适应探索剂量组合,建立TDS并推荐II期剂量组(RS2D)。
- 第二阶段随机分配患者至RS2D组合,筛选并确定最佳生物剂量组合(OBDC)。
- 模拟研究显示PROComb操作特性优于传统基于模型和模型辅助设计。
核心结论
- PROComb 是一种实用且稳健的随机化设计,能以最小假设优化药物联合试验的剂量组合并便于实施。
研究设计与样本
- 两阶段随机化设计:第一阶段整合多源数据自适应探索剂量组合空间并建立TDS、推荐RS2D;第二阶段随机分配患者至RS2D组合以识别OBDC。
- 开发了三个PROComb版本以减轻阶段间漂移。
主要发现
- 模拟研究表明PROComb相比传统基于模型和模型辅助设计取得有利的操作特性。
关键数值与推荐
- TDS定义为具有可接受毒性和有前景疗效的剂量集合。
- 第一阶段结束时构建推荐II期剂量组(RS2D)。
- 第二阶段通过随机化监测、筛选和识别最佳生物剂量组合(OBDC)。
临床怎么用
- 可用于肿瘤药物联合开发中替代“越多越好”范式,通过随机化优化剂量组合并识别OBDC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The US Food and Drug Administration's Project Optimus has initiated a paradigm shift in oncology drug development from "more is better" to "less is more." Methodological development for combination therapy trials remains limited due to their complex dose-combination space and the need to integrate multi-source data, including toxicity, clinical efficacy, and biological antitumor outcomes such as pharmacodynamic (PD) activity. We propose PROComb, a practical and robust design with randomization to optimize dose combinations, to address these challenges with minimal assumptions and to facilitate practical implementation. In the first stage, the complex dose-combination space is efficiently explored through the integration of multi-source data and the inherent relationships among different dose-outcomes. Patients are adaptively assigned to dose combinations to establish a therapeutic dose space (TDS), defined as the set of doses with acceptable toxicity and promising efficacy. A recommended Stage II dose set (RS2D) is constructed at the end of Stage I. In the second stage, patients are randomized to RS2D combinations for further monitoring, screening and identification of the optimal biologic dose combination (OBDC). Three PROComb versions are developed to mitigate potential between-stage drift. Simulation studies demonstrate that PROComb achieves favorable operating characteristics compared with conventional model-based and model-assisted designs.
引用
- Qiu Y, Li M. PROComb: A Practical and Robust Design With Randomization to Optimize Dose Combinations in Drug Combination Trials. Stat Med. 2026. PMID: 42773876. doi:10.1002/sim.70743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。